Aptar Pharma has formed an alliance with Becton, Dickinson & Co to develop new self-injection devices that will tap into the strong growth in injectable drugs.
BD says a brand new facility and sustainable pricing will allow the company to compete as it enters the generics market following FDA approval of its first injectable drug.
The insulin delivery devices thriving in today's market will slowly
be replaced as new and better technologies continue to rise from
the R&D pipeline. For current market leader, Novo Nordisk, this
threat is particularly dangerous.
BD Biosciences has acquired Atto Bioscience in a deal worth $25
million (€20m), allowing it to enter the emerging high content cell
analysis market and enhancing its presence in the pharmaceutical
and biotechnology sectors.
